In May 2024, Knight entered into an agreement with Ironshore Pharmaceuticals & Development, Inc., a wholly owned subsidiary of Ironshore Therapeutics, Inc. (now part of Collegium Pharmaceutical, Inc.; ...

Elite received approval from the Food and Drug Administration for a generic version of Vyvanse (lisdexamfetamine dimesylate) capsules in strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg ...

Introduction Attention-deficit/hyperactivity disorder (ADHD) is one of the most prevalent neurodevelopmental disorders and is a persistent pattern of inattention and ...

ADHD is not a disease but a malfunctioning composition of cognitive traits that exist on more functional levels even in the general population, such as “attention control” (concentration) and ...

Attention deficit hyperactivity disorder: pharmacological and psychological interventions in children, young people and adults.2008. London: The British Psychological Society and the Royal College ...

Attention deficit hyperactivity disorder (ADHD) affects around 1–3% of children. There is a high level of comorbidity with developmental and learning problems as well as with a variety of psychiatric ...

Attention-Deficit Hyperactivity Disorder (ADHD) is one of the most common mental health disorders ...

Exercise offers both physical and mental health benefits. When combined with other treatments, regular exercise can help with ...

Adults with attention-deficit/hyperactivity disorder (ADHD) are more frequently presenting for diagnosis and treatment. Medication is considered to be appropriate ...

Purpose: The pharmacology, pharmacokinetics, clinical efficacy, safety, drug interactions, dosage and administration, and place in therapy of atomoxetine in the treatment of attention-deficit ...